Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase

Journal of Medicinal Chemistry

Volumn 42, Issue 25, 1999, Pages 5241-5253

  Ding, Charles Z ^a   Batorsky, Roberta ^a   Bhide, Rajeev ^a   Chao, Hannguang J ^a   Cho, Young ^a   Chong, Saeho ^a   Gullo Brown, Johnni ^a   Guo, Peng ^a   Kim, Soong Hoon ^a   Lee, Frank ^a   Leftheris, Katerina ^a   Miller, Arthur ^a   Mitt, Toomas ^a   Patel, Manorama ^a   Penhallow, Becky A ^a   Ricca, Carol ^a   Rose, William C ^a   Schmidt, Robert ^a   Slusarchyk, William A ^a   Vite, Gregory ^a   Yan, Ning ^a   Manne, Veeraswamy ^a   Hunt, John T ^a   more..

^a Bristrol Meyers Squibb P ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; ONCOPROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN 3T3; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CELL LINE, TRANSFORMED; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HYDROGEN BONDING; IMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033576607     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990391w     Document Type: Article

References (24)

1. Lowry, D. R.; Willumson, B. M. Function and Regulation of Ras; Annual Reviews Inc.: Palo Alto, CA, 1993; Vol. 62.
2. Kiyoko, K.; Cox, A. D.; Hisaka, M. M.; Graham, S. M.; Buss, J. E.; Der, C. J. Isoprenoid Addition to Ras Protein is the Critical Modification for its Membrane Association and Transforming Activity. Proc. Natl. Acad. Sci. 1992, 89, 6403-6407.
3. Cox, A. D.; Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1997, 1333, F51-F71.
4. Lebowitz, P. F.; Prendergast, G. C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 1998, 17, 1439-1445.
5. Huang, C.-C.; Casey, P. J.; Fierke, C. A. Evidence for a Catalytic Role of Zinc in Protein Farnesyltransferase. J. Biol. Chem. 1997, 272, 20-23.
6. Graham, S. L. Inhibitors of protein farnesylation: a new approach to cancer chemotherapy. Exp. Opin. Ther. Patents 1995, 5, 1269-1285.
7. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B. R.; Carboni, J. M.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, Cell Active Non-Thiol Tetrapeptide Inhibitors of Farnesyl Transferase. J. Med. Chem. 1966, 39, 353-358.
8. DeSolms, S. J.; Garsky, V. M.; Giuliani, E. A.; Gomez, R. P.; Graham, S. L.; Stokker, G. E.; Wiscount, C. M. Inhibitors of Farnesyl-Protein Transferase. WO 95/09001, Apr 6, 1995.
9. Nagasu, T.; Yoshimatsu, K.; Rowell, C.; Lewis, M. D.; Garcia, A. M. Inhibition of Human Tumor Xenograft Growth by Treatment with the Farnesyl Transferase Inhibitor B956. Cancer Res. 1995, 55, 5310-5314.
10. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion. Cancer Res. 1995, 55, 4243-4247.
11. Kohl, N. E.; Omer, C. A.; Conner, M. W.; Anthony, N.; Davide, J. P.; DeSolms, S. J.; Giuliani, E. A.; Gomez, R. P.; Graham, S. L.; Hamilton, K.; Handt, L. K.; Hartman, G. D.; Koblan, K. S.; Kral, A. M.; Miller, P. J.; Mosser, S. D.; O'Neill, T. J.; Rands, E.; Schaber, M. D.; Gibbs, J. B.; Oliff, A. I. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1995, 1, 792-797.
12. Zujewski, J.; Horak, I. D.; Woestenborghs, R.; Chiao, J.; Cusack, G.; Kohler, D.; Kremer, A. B.; Cowan, K. H. In Proc. Am. Assoc. Cancer Res. 1998, 39, 270, Abstract #1848.
13. Liu, M.; Lee, S.; Yaremko, B.; Chen, J.; Dell, J.; Nielsen, L.; Lipari, P.; Ferrari, E.; Malkowski, M.; Bryant, M. S.; Njoroge, F. G.; Taveras, A. G.; Doll, R. J.; Kirschmeier, P.; Nomeir, A. A.; Kelly, J.; Remiszewski, S.; Mallams, A. K.; Afonso, A.; Hollinger, F. P.; Cooper, A. B.; Liu, Y.-T.; Rane, D.; Girijavallabhan, V.; Ganguly, A. K.; Bishop, W. R. SCH 66336, an orally bioavailable tricyclic farnesyl protein transferase inhibitor, demonstrates broad and potent in-vivo antitumor activity. Proc. Am. Assoc. Cancer Res. 1998, 39, 270, Abstract #1843.
14. Graham, S. L.; Williams, T. M. Inhibitors of Farnesyl-Protein Transferase. WO 95/00497, Jan 5, 1995.
15. Manne, V.; Ricca, C. S.; Brown, J. G.; Tuomari, A. V.; Yan, N.; Patel, D. V.; Schmidt, R.; Lynch, M. J.; C. P. Ciosek, J.; Carboni, J. M.; Robinson, S.; Gordon, E. M.; Barbacid, M.; Seizinger, B. R.; Biller, S. A. Ras Farnesylation as a Target for Novel Antitumor Agents: Potent and Selective Farnesyl Diphosphate Analogue Inhibitors of Farnesyltransferase. Drug Dev. Res. 1995, 34, 121-137.
16. Manne, V.; Yan, N.; Carboni, J. M.; Tuomari, A. V.; Ricca, C. S.; Brown, J. G.; Andahazy, M. L.; Schmidt, R. J.; Patel, D.; Zahler, R.; Weinmann, R.; Der, C. J.; Cox, A. D.; Hunt, J. T.; Gordon, E. M.; Barbacid, M.; Seizinger, B. R. Bisubstrate Inhibitors of Farnesyltransferase: A Novel Class of Specific Inhibitors of Ras Transformed Cells. Oncogene 1995, 10, 1763-1779.
17. Leftheris, K.; Kline, T.; Vite, G.; Cho, Y. H.; Bhide, R. S.; Patel, M. M.; Schmidt, R.; Carboni, J. M.; Yan, N.; Ricca, C.; Gullo-Brown, J. L.; Andahazy, M. L.; Barbacid, M.; Seizinger, B. R.; Meyers, C. A.; Hunt, J. T.; Manne, V. Highly Potent Nonprodrug Inhibitors of Ras Farnesyl Transferase Possessing Whole Cell Activity. J. Med. Chem. 1996, 39, 224-236.
18. Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Bock, R. L.; Conner, M. W.; Davide, J. P.; Hamilton, K.; Koblan, K. S.; Kohl, N. E.; Kral, A. M.; Mosser, S. D.; Omer, C. A.; Pompliano, D. L.; Rands, E.; Schaber, M. D.; Shah, D.; Wilson, F. R.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Smith, R. L. 2-Substituted Piperazines as Constrained Amino Acids. Application to the Synthesis of Potent, Non Carboxylic Acid Inhibitors of Farnesyltransferase. J. Med. Chem. 1996, 39, 1345-1348.
19. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Cheng, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists. J. Med. Chem. 1988, 31, 2235-2246.
20. J. C. Marsters, J.; McDowell, R. S.; Reynolds, M. E.; Oare, D. A.; Somers, T. C.; Stanley, M. S.; Rawson, T. E.; Struble, M. E.; Burdick, D. J.; Chan, K. S.; Duarte, C. M.; Paris, K. J.; Tom, J. Y. K.; Wan, D. T.; Xue, Y.; Burnier, J. P. Benzodiazepine Peptidomimetic Inhibitors of Farnesyltransferase. Bioorg. Med. Chem. 1994, 2, 949-957.
21. Breslin, M. J.; deSolms, S. J.; Giuliani, E. A.; Stocker, G. E.; Graham, S. L.; Pompliano, D. L.; Mosser, S. D.; Hamilton, K. A.; Hutchinson, J. H. Potent, Non-Thiol Inhibitors of Farnesyltransferase. Bioorg. Med. Chem. Lett. 1998, 8, 3311-3316.
22. Geran, R. I.; Greenberg, N. H.; McDonald, M. M.; Abbott, B. J. Modified Protocol for the Testing of New Synthetics in the L1210 Lymphoid Leukemia Model in the DR&G Program. Natl. Cancer Inst. Monogr. 1977, 45, 151-153.
23. Gehan, G. A. A Generalized Wilcoxon Test for Comparing Abitrarily Singly-Censored Samples. Biometrika 1985, 52, 203-233.
24. Buschauer, A.; Sattler, H.-J.; Schunack, W. Synthese von 2-(2-Aminoethyl)-4-hydroxymethyl-imidazol. Arch. Pharm. (Weinheim, Ger.) 1982, 315, 563-566.